Log in

NASDAQ:PRTA - Prothena Stock Price, Forecast & News

-0.11 (-0.85 %)
(As of 12/16/2019 07:26 AM ET)
Today's Range
Now: $12.85
50-Day Range
MA: $10.72
52-Week Range
Now: $12.85
Volume131,664 shs
Average Volume233,282 shs
Market Capitalization$512.72 million
P/E RatioN/A
Dividend YieldN/A
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PRTA



Sales & Book Value

Annual Sales$950,000.00
Book Value$8.10 per share


Net Income$-155,650,000.00
Net Margins-10,450.00%


Market Cap$512.72 million
Next Earnings Date2/13/2020 (Estimated)

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Prothena (NASDAQ:PRTA) Frequently Asked Questions

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) released its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.54) by $0.05. The biotechnology company had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.15 million. Prothena had a negative return on equity of 26.02% and a negative net margin of 10,450.00%. View Prothena's Earnings History.

When is Prothena's next earnings date?

Prothena is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Prothena.

What price target have analysts set for PRTA?

3 equities research analysts have issued 12 month price objectives for Prothena's stock. Their forecasts range from $9.00 to $14.00. On average, they expect Prothena's stock price to reach $12.26 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View Analyst Price Targets for Prothena.

What is the consensus analysts' recommendation for Prothena?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prothena.

Has Prothena been receiving favorable news coverage?

Media headlines about PRTA stock have trended somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prothena earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Prothena.

Who are some of Prothena's key competitors?

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BIOLINERX LTD/S (BLRX), Perrigo (PRGO), Celgene (CELG) and Synergy Pharmaceuticals (SGYP).

Who are Prothena's key executives?

Prothena's management team includes the folowing people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)
  • Mr. Tran B. Nguyen, CFO & COO (Age 45)
  • Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)
  • Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 46)

Who are Prothena's major shareholders?

Prothena's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (7.57%), Great Point Partners LLC (5.18%), Millennium Management LLC (3.08%), State Street Corp (3.00%), Tang Capital Management LLC (1.06%) and Man Group plc (0.24%). View Institutional Ownership Trends for Prothena.

Which institutional investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC, Man Group plc, Orbimed Advisors LLC, Russell Investments Group Ltd. and Rhumbline Advisers. View Insider Buying and Selling for Prothena.

Which institutional investors are buying Prothena stock?

PRTA stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Great Point Partners LLC, Tang Capital Management LLC, Endurant Capital Management LP, Campbell & CO Investment Adviser LLC, California Public Employees Retirement System, Meeder Asset Management Inc. and Focused Wealth Management Inc. View Insider Buying and Selling for Prothena.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $12.85.

How big of a company is Prothena?

Prothena has a market capitalization of $512.72 million and generates $950,000.00 in revenue each year. The biotechnology company earns $-155,650,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis. Prothena employs 59 workers across the globe.View Additional Information About Prothena.

What is Prothena's official website?

The official website for Prothena is http://www.prothena.com/.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]

MarketBeat Community Rating for Prothena (NASDAQ PRTA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  490 (Vote Outperform)
Underperform Votes:  369 (Vote Underperform)
Total Votes:  859
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel